R Sinha1, D Roxby, A Bersten. 1. Department of Haematology and Genetic Pathology, School of Medicine, Flinders University, South Australia, Australia. sinh0001@flinders.edu.au
Abstract
BACKGROUND AND OBJECTIVES: A massive transfusion response (MTR) was introduced in 2007 to provide blood and blood products in a timelier manner. Aim of this study was to determine whether implementation of the MTR was associated with a change in clinical practice or mortality. MATERIALS AND METHODS: All MTR activations from 2008 to 2011 were included in the study. Patients who had received a massive transfusion (MT ≥ 10 units RBC in 24 h) as part of the MTR (MT-MTR) were compared with a historical group of MT patients (MT-Pre-MTR) from 2004 to 2006. Blood product usage including fresh frozen plasma (FFP) : RBC and platelet : RBC ratios and mortality were compared between the two groups. RESULTS: Out of 169 MTR activations, 13 patients (8%) did not use any blood products, 73 (43%) used <10 units of RBC in a 24-h period and 83 received a MT. The median number of units of FFP and platelets transfused in the MT-MTR group were 10 [interquartile range (IQR) 7-17] vs 6 (5-10) [P < 0·001] and 3 (IQR 2-4) vs 2 (IQR 1-3) [P < 0·001] in the MT-Pre-MTR group of patients, respectively. The MT-MTR group received a higher 24-h FFP : RBC ratio (1 : 1·4 vs 1 : 2·4, P < 0·001). Overall mortality between the MT-MTR and MT-Pre-MTR groups (29% vs 23%, P = 0·43) and 90-day mortality was 25% vs 29% (P = 0·40), respectively. CONCLUSION: Although there has been a significant change in transfusion practice in MT patients using a MTR, no change in mortality could be documented using such a protocol.
BACKGROUND AND OBJECTIVES: A massive transfusion response (MTR) was introduced in 2007 to provide blood and blood products in a timelier manner. Aim of this study was to determine whether implementation of the MTR was associated with a change in clinical practice or mortality. MATERIALS AND METHODS: All MTR activations from 2008 to 2011 were included in the study. Patients who had received a massive transfusion (MT ≥ 10 units RBC in 24 h) as part of the MTR (MT-MTR) were compared with a historical group of MT patients (MT-Pre-MTR) from 2004 to 2006. Blood product usage including fresh frozen plasma (FFP) : RBC and platelet : RBC ratios and mortality were compared between the two groups. RESULTS: Out of 169 MTR activations, 13 patients (8%) did not use any blood products, 73 (43%) used <10 units of RBC in a 24-h period and 83 received a MT. The median number of units of FFP and platelets transfused in the MT-MTR group were 10 [interquartile range (IQR) 7-17] vs 6 (5-10) [P < 0·001] and 3 (IQR 2-4) vs 2 (IQR 1-3) [P < 0·001] in the MT-Pre-MTR group of patients, respectively. The MT-MTR group received a higher 24-h FFP : RBC ratio (1 : 1·4 vs 1 : 2·4, P < 0·001). Overall mortality between the MT-MTR and MT-Pre-MTR groups (29% vs 23%, P = 0·43) and 90-day mortality was 25% vs 29% (P = 0·40), respectively. CONCLUSION: Although there has been a significant change in transfusion practice in MT patients using a MTR, no change in mortality could be documented using such a protocol.
Authors: Diego Rossetti; Salvatore Giovanni Vitale; Giorgio Bogani; Agnese Maria Chiara Rapisarda; Ferdinando Antonio Gulino; Luigi Frigerio Journal: Updates Surg Date: 2015-03-27
Authors: J C Oldroyd; K M Venardos; N J Aoki; A J Zatta; Z K McQuilten; L E Phillips; N Andrianopoulos; D J Cooper; P A Cameron; J P Isbister; E M Wood Journal: BMC Res Notes Date: 2016-10-06
Authors: Alexander P J Vlaar; Joanna C Dionne; Sanne de Bruin; Marije Wijnberge; S Jorinde Raasveld; Frank E H P van Baarle; Massimo Antonelli; Cecile Aubron; Jacques Duranteau; Nicole P Juffermans; Jens Meier; Gavin J Murphy; Riccardo Abbasciano; Marcella C A Müller; Marcus Lance; Nathan D Nielsen; Herbert Schöchl; Beverley J Hunt; Maurizio Cecconi; Simon Oczkowski Journal: Intensive Care Med Date: 2021-10-22 Impact factor: 17.440
Authors: Matthew A Warner; Ryan D Frank; Timothy J Weister; Nageswar R Madde; Ognjen Gajic; Daryl J Kor Journal: Anesth Analg Date: 2020-08 Impact factor: 6.627
Authors: Luke J Matzek; Emil B Kurian; Ryan D Frank; Timothy J Weister; Ognjen Gajic; Daryl J Kor; Matthew A Warner Journal: Vox Sang Date: 2021-08-01 Impact factor: 2.996
Authors: Jessica E van der Meij; Leo M G Geeraedts; Saskia J M Kamphuis; Nimmi Kumar; Tony Greenfield; Geoff Tweeddale; David Rosenfeld; Scott K D'Amours Journal: ANZ J Surg Date: 2019-09-09 Impact factor: 1.872